• Explore /
  • Poster
  • / ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.

ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.

Abstract Poster

Authors

null

Jie Wang

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Jie Wang , Jianchun Duan , Ligang Xing , Yuping Sun , Wei Guo , Haiying Wang , Jianhua Chen , Liang Han , Baogang Liu , Qiming Wang , Ying Hu , Hongying Wei , Chuan Li , Qiqi Huang , Yiwei Dong , Qiong Wu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT05276609

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3017)

DOI

10.1200/JCO.2023.41.16_suppl.3017

Abstract #

3017

Poster Bd #

215

Abstract Disclosures

Similar Posters

First Author: Sekwon Jang

First Author: Alexander I. Spira

First Author: Susanna Varkey Ulahannan

First Author: Judy S. Wang